Key Takeaways
- • Construction Pipeline Receding to 10-Year Low: Lab and R&D construction activity is projected to hit a 10-year low, easing oversupply pressure and establishing healthier market fundamentals across major U.S. life sciences hubs after two years of excess capacity.
- • Capital Markets Re-Engagement Signals Cycle Shift: Equity market gains and renewed venture capital activity are accelerating heading into 2026, historically preceding increased lab space demand and signaling transition from cautious decision-making to opportunistic investment positioning.
- • Investment Activity Poised to Accelerate: Transaction volume in life sciences real estate is expected to gain momentum as policy uncertainty diminishes and financing conditions improve, with companies investing in lab facilities at unprecedented levels to reinforce the U.S. position as a global life sciences hub.
- • Market Leaders Consolidating Position: Alexandria Real Estate Equities, BioMed Realty (Blackstone portfolio), Healthpeak Properties, Ventas, and Longfellow remain the five largest owners of U.S. life sciences real estate, positioned to capitalize on recovery phase dynamics.
- • Demand Stabilization and Positive Indicators: Multiple key performance metrics moved in positive directions at the end of 2025 and are projected to improve further in 2026, including stabilized space demand and improved capital market conditions.
Summary
The U.S. life sciences real estate market is entering a critical inflection point in 2026 after two years characterized by oversupply, conservative capital allocation decisions, and constrained transaction activity. According to CBRE's 2026 U.S. Life Sciences Trends report, several structural forces are now aligning to create conditions for a disciplined and potentially opportunistic recovery phase. The construction pipeline for lab and R&D facilities is projected to reach a 10-year low, a significant development that should ease the supply-demand imbalance that has pressured fundamentals in major life sciences clusters across the country.
Capital market dynamics are shifting meaningfully in favor of renewed investment activity. Equity market gains and accelerating venture capital activity—both historically reliable leading indicators for increased laboratory space demand—were already gaining momentum heading into 2026. These positive signals suggest that institutional capital is growing more confident about deploying into life sciences real estate opportunities, a departure from the cautious stance that characterized the 2024-2025 period. Policy uncertainty is expected to fade further, and financing conditions are projected to improve, creating a more favorable backdrop for transaction acceleration in key markets.
Demand fundamentals appear to have stabilized after two years of softness. Multiple data points related to occupancy, rent growth, and space utilization moved in positive directions at the end of 2025 and are expected to improve further throughout 2026. Critically, companies are investing in lab facility infrastructure at unprecedented levels, reinforcing the nation's competitive position as a global life sciences innovation hub. This sustained capital deployment at the company level, combined with improving REIT and institutional investor appetite, suggests conviction about long-term sector tailwinds.
However, the recovery path will not be uniform across all markets and asset classes. Expiring patent portfolios, accelerating scientific innovation, surging domestic manufacturing activity, and intensifying global competition are reshaping the sector in ways that will create winners and losers among real estate assets and geographic clusters. The five largest life sciences real estate owners—Alexandria Real Estate Equities, BioMed Realty (a Blackstone portfolio company), Healthpeak Properties, Ventas, and Longfellow—are positioned to benefit from this recovery given their scale and market positioning, though selective investment will remain critical.
For institutional investors and alternative asset managers, the turning point presents a dual challenge: identifying which markets and asset types will benefit most from the structural shifts underway, while timing entry into a recovery phase that is expected to be more disciplined than prior cycles. The combination of receding construction, stabilizing demand, and re-engaging capital suggests the foundation for improved returns is forming, but execution and market selection will be decisive.
Capital market dynamics are shifting meaningfully in favor of renewed investment activity. Equity market gains and accelerating venture capital activity—both historically reliable leading indicators for increased laboratory space demand—were already gaining momentum heading into 2026. These positive signals suggest that institutional capital is growing more confident about deploying into life sciences real estate opportunities, a departure from the cautious stance that characterized the 2024-2025 period. Policy uncertainty is expected to fade further, and financing conditions are projected to improve, creating a more favorable backdrop for transaction acceleration in key markets.
Demand fundamentals appear to have stabilized after two years of softness. Multiple data points related to occupancy, rent growth, and space utilization moved in positive directions at the end of 2025 and are expected to improve further throughout 2026. Critically, companies are investing in lab facility infrastructure at unprecedented levels, reinforcing the nation's competitive position as a global life sciences innovation hub. This sustained capital deployment at the company level, combined with improving REIT and institutional investor appetite, suggests conviction about long-term sector tailwinds.
However, the recovery path will not be uniform across all markets and asset classes. Expiring patent portfolios, accelerating scientific innovation, surging domestic manufacturing activity, and intensifying global competition are reshaping the sector in ways that will create winners and losers among real estate assets and geographic clusters. The five largest life sciences real estate owners—Alexandria Real Estate Equities, BioMed Realty (a Blackstone portfolio company), Healthpeak Properties, Ventas, and Longfellow—are positioned to benefit from this recovery given their scale and market positioning, though selective investment will remain critical.
For institutional investors and alternative asset managers, the turning point presents a dual challenge: identifying which markets and asset types will benefit most from the structural shifts underway, while timing entry into a recovery phase that is expected to be more disciplined than prior cycles. The combination of receding construction, stabilizing demand, and re-engaging capital suggests the foundation for improved returns is forming, but execution and market selection will be decisive.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.